<DOC>
	<DOCNO>NCT01651949</DOCNO>
	<brief_summary>This study design evaluate immunogenicity tolerability 9vHPV ( 9-valent HPV vaccine , V503 ) 16- 26-year old men woman . The overall goal bridge 9vHPV efficacy finding young woman young men base demonstration similar immunogenicity safety profile . The primary hypothesis 9vHPV induces antibody response 4 week postdose 3 heterosexual male non-inferior antibody response young woman .</brief_summary>
	<brief_title>Multivalent HPV ( Human Papillomavirus ) Vaccine Study 16- 26-Year Old Men Women ( V503-003 )</brief_title>
	<detailed_description>Study participant administer 3-dose regimen 9vHPV . They assess immunogenicity 1 month follow completion vaccination . All participant follow safety total 12 month .</detailed_description>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Good physical health Has never Papanicolaou test ( Pap , cervical anal ) normal Pap test result Other inclusion criterion discuss investigator History severe allergic reaction require medical intervention Currently enrol clinical trial If participant female , pregnant Currently immunocompromised receive immunosuppressive therapy last year Positive test HPV History HPVrelated external genital lesion HPVrelated anal lesion anal cancer If participant female , history abnormal cervical biopsy result Other exclusion criterion discuss investigator</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>